This paper is in the following e-collection/theme issue:

Clinical Information and Decision Making (2004) Adverse Drug Events Detection, Pharmacovigilance and Surveillance (221) Drug Repurposing and Off-Label Use (29) Digital Health Reporting Standards, Quality and Transparency in e-Research (142)

Published on in Vol 27 (2025)

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/65872, first published .
Detection of Clinically Significant Drug-Drug Interactions in Fatal Torsades de Pointes: Disproportionality Analysis of the Food and Drug Administration Adverse Event Reporting System

Detection of Clinically Significant Drug-Drug Interactions in Fatal Torsades de Pointes: Disproportionality Analysis of the Food and Drug Administration Adverse Event Reporting System

Detection of Clinically Significant Drug-Drug Interactions in Fatal Torsades de Pointes: Disproportionality Analysis of the Food and Drug Administration Adverse Event Reporting System

Authors of this article:

Huanhuan Ji1 Author Orcid Image ;   Meiling Gong1, 2 Author Orcid Image ;   Li Gong3 Author Orcid Image ;   Ni Zhang4 Author Orcid Image ;   Ruiou Zhou1 Author Orcid Image ;   Dongmei Deng1 Author Orcid Image ;   Ya Yang1 Author Orcid Image ;   Lin Song1 Author Orcid Image ;   Yuntao Jia1 Author Orcid Image
Article Authors Cited by (2) Tweetations Metrics

Journals

  1. Shi W, Zhang Y, Ning J. Robust spurious drug–drug interaction detection via chi-square-guided bidirectional attention mechanism. Engineering Applications of Artificial Intelligence 2025;162:112331 View
  2. Matos C, Ali N, Augusto A, Algarvio R, Figueirinha J, Conceição J. Predictive value of the hERG assay for anticipating the arrhythmogenic potential of new drugs. Drug Discovery Today 2026:104615 View